Current clinical practice gaps in the treatment of intermediate- and high-risk non-muscle-invasive bladder cancer (NMIBC) with emphasis on the use of bacillus Calmette-Guerin
(BCG): results of an international individual patient data survey (IPDS).
DNA vaccination boosts Bacillus Calmette-Guerin
protection against mycobacterial infection in zebrafish.
The primary mechanism of attenuation of bacillus Calmette-Guerin
is a loss of secreted lytic function required for invasion of lung interstitial tissue," Proceedings of the National Academy of Sciences of the United States of America, vol.
Brossman, "Experience with bacillus Calmette-Guerin
in patients with superficial bladder carcinoma," The Journal of Urology, vol.
produced a single nest-PCR 133-bp band as we expected and showed a typical Mycobacterium tuberculosis pattern.
(BCG), a live attenuated vaccine prepared from a strain of Mycobacterium bovis, is routinely administered to neonates for the prevention of serious infections by Mycobacterium tuberculosis in endemic countries.
Female gender and carcinoma in situ in prostatic urethra are prognostic factors for recurrence, progression, and disease specific mortality in T1G3 bladder cancer patients treated with Bacillus Calmette-Guerin
Prevention relies on screening programs and vaccination with the bacillus Calmette-Guerin
Tuberculosis, bacillus Calmette-Guerin
vaccination, and allergic disease: findings from the International Study of Asthma and Allergies in Childhood Phase Two.
We know from numerous efficacy trials over several decades that bacillus Calmette-Guerin
(BCG) has 60-80% protective efficacy against severe forms of tuberculosis (TB) in children, particularly meningitis, but that its efficacy against pulmonary disease varies geographically.
Intravesical bacillus Calmette-Guerin
is superior to mitomycin C in reducing tumour recurrence in high-risk superficial bladder cancer: a meta-analysis of randomized trials.
The trial intends to enrol around 93 patients and it is designed to determine whether vaccination with HS-410 after transurethral resection of bladder tumour and bacillus Calmette-Guerin
extends the time to disease recurrence compared to placebo.